Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder
- First Online:
- 217 Downloads
The optimal dose for achieving the maximum antidepressive effect of selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenalin reuptake inhibitors (SNRIs) remains a controversial issue. The varying sensitivity of scales that measure the severity of depression is one of the many factors affecting the evaluation of the dose–response relationship with antidepressants.
To determine if the 6-item Hamilton rating scale for depression (HAM-D6) demonstrates a clearer association between dose and antidepressive effect compared with the 17-item Hamilton rating scale for depression (HAM-D17) for fixed doses of duloxetine hydrochloride (40, 60, 80, and 120 mg daily) from six double-blind, randomized, placebo-controlled clinical trials assessing safety and efficacy in the acute treatment of patients with DSM-IV-defined major depressive disorder (MDD).
Mantel–Haenszel adjusted effect sizes were determined by dose for change from baseline to endpoint in HAM-D6 and HAM-D17 scores from the six studies. To confirm, assessments were repeated on the subset of the population corresponding to the 70% of patients with the longest duration of treatment regardless of study, treatment, dose, geography, or completion status.
For the majority of assessments, HAM-D6 effect sizes were numerically larger than those estimated from the HAM-D17. Findings support that duloxetine 60 mg daily is the best effective dose.
In this assessment of patients with MDD, the HAM-D6 was shown to be more sensitive compared with the HAM-D17 at detecting treatment effects. These findings are consistent with published results of other effective antidepressants.
KeywordsDuloxetine Cymbalta Depression Dose–response HAM-D6 HAM-D17
- Angst J et al (1989) Consensus conference on the methodology of clinical trials of antidepressants. Pharmacopsychiatry 22:3–7Google Scholar
- Borsboom D (2005) Measuring the mind. Conceptual issues in contemporary psychometrics. Cambridge University Press, CambridgeGoogle Scholar
- Burroughs VJ et al (2002a) Cultural and genetic diversity and America: the need for individualized pharmaceutical treatment. National Pharmaceutical Council and National Medical Association. Last accessed on 12/06/2005 available from: http://www.npcnow.org/resources/PDFs/CulturalFINAL.pdf
- DUAG (Danish University Antidepressant Group) (1999) Clomipramine dose–effect study in patients with depression: clinical endpoints and pharmacokinetics. Clin Pharmacol Ther 66:152–165Google Scholar
- Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic, New York, NYGoogle Scholar
- Preskorn SH (1998) Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ (eds) European cooperation in the field of scientific and technical research. European Commission, Brussels, Belgium, pp 45–61Google Scholar
- Ruhe H et al (2005) Clinical use of the Hamilton Depression Scale: is increased efficiency possible? A post hoc comparison of the Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression and Symptom Checklist-90 scores. Compr Psychiatry 46:417–427PubMedCrossRefGoogle Scholar